FY2025 · ended Dec 31, 2025 · Revenue $20,000, +0.0% YoY · Filed Mar 31, 2026
Skinvisible, Inc. (SKVI) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $20,000 and a net loss of $1.1 million. Free cash flow was -$42,496.
Revenue (TTM)
$20,000
+0.0% vs year-ago TTM
Net income (TTM)
$-1.03M
-95.6% vs year-ago TTM
Operating cash flow (TTM)
$3,838
+105.5% vs year-ago TTM
Free cash flow
$-42,496
EPS
$-0.11
+78.8% vs prior year
Dividend per share
None
Shares outstanding
5.40M
+1.6% vs prior year
Net cash
—
Operating margin
-2294.9%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SKVI (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Las Vegas, NV
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1085277
- Former names
- SKINVISIBLE INC (until Aug 14, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $20,000 | $20,000 | $20,000 | $279,296 | $663,426 |
| Operating income | -$496,315 | -$589,589 | -$490,375 | -$238,432 | $188,080 |
| Net income | -$1.1M | -$565,654 | -$2.4M | -$1.2M | -$1.1M |
| Diluted EPS | — | -$0.11 | -$0.52 | -$0.27 | -$0.24 |
| Operating cash flow | -$38,410 | -$69,834 | -$77,157 | $45,170 | $374,605 |
| Free cash flow | -$42,496 | — | — | — | — |
| Total assets | $127,567 | $158,217 | $162,869 | $246,793 | $227,299 |
| Total liabilities | $10.4M | $9.4M | $9.2M | $6.9M | $5.6M |
| Stockholders' equity | -$10.3M | -$9.2M | -$9.0M | -$6.6M | -$5.4M |
| Cash and investments | $2,620 | $10,336 | $888 | $81,378 | $66,037 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Mar 31, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | Nov 13, 2025 | Sep 30, 2025 |
| 10-Q | Quarterly report | Aug 13, 2025 | Jun 30, 2025 |
| 10-Q | Quarterly report | May 14, 2025 | Mar 31, 2025 |
All 391 Skinvisible, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.